Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability (2022)
- Authors:
- Autor USP: LEÃO, MATHEUS DE CASTRO - FCF
- Unidade: FCF
- Sigla do Departamento: FBA
- DOI: 10.11606/T.9.2022.tde-30112022-111709
- Subjects: ARTERIOSCLEROSE; POLARIZAÇÃO; INFLAMAÇÃO
- Keywords: Ácido docosahexaenoico; Aterosclerose; Atherosclerosis; Docosaheanoic acid; Inflamação; Inflammation; Nanocápsulas; Nanocapsules; Polarização; Polarization
- Agências de fomento:
- Language: Inglês
- Abstract: Cardiovascular diseases (CVDs) are the main cause of mortality worldwide, being the ischemic heart disease responsible for 85% of deaths. Atherosclerosis is a chronic inflammation of the arteries that underlies ischemic forms of CVD and involves the innate and adaptive immune systems, from initial fatty streak formation to atherosclerotic plaque ruptures, which defines the beginning and end stages of disease, respectively. Recent research on the reduction of systemic inflammation in order to treat CVD is controversial, since results show that this reduced inflammation can also increase patient susceptibility to general infection. Therefore, new tissue-targeting strategies are necessary. Docosahexaenoic fatty acid (DHA) is a natural bioactive precursor of pro-resolving oxylipins that can reduce inflammation. Based on these factors, the objective of this study was to develop a nanocapsule containing algae oil as a DHA source and apply anti-PECAM-1 on its surface to drive it to the inflamed endothelium. Initially, a surface-functionalized metal-complex multi-wall nanocapsule containing algae oil in its nucleus (MLNC-DHA-a1) was developed. This nanocapsules presented a mean diameter of 163 ± 5 nm, was spherical in shape, showed 94.80% conjugation efficiency using 200 µg/mL of anti-PECAM-1 on the surface, and did not show significant toxicity toward HUVECs at concentrations from 0.14 to 2.90x1011 nanocapsules/mL. The nanocapsules were also stable for 2 h, sufficient time to allow for clinical applications. In cell viability assays, concentrations of 0.14 to 1.40x1011 nanocapsules/mL did not significantly affect the viability of immortalized murine macrophages (RAW 264.7) and U-937 cells after 24, 48, and 72 h of treatment. Finally, macrophages were incubated with 0.75x1011 MLNC-DHA-a1 nanocapsules/mL for 4 h and showed a significant uptake, observed using dark-field hyperspectral microscopy(CytoViva®). Once inside murine macrophages (RAW 264.7), MLNC-DHA-a1 nanocapsules promoted a strong increase in M2 phenotype polarization compared to non-treated control cells. Our results suggest that DHA-enriched algae oil, as part of a lipid core nanocapsules, does not reduce cell viability and improves macrophage phenotype, making it a promising potential therapy for controlling chronic inflammation and healing or stabilizing atherosclerotic plaques
- Imprenta:
- Data da defesa: 10.10.2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-sa
-
ABNT
LEÃO, Matheus de Castro. Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability. 2022. Tese (Doutorado) – Universidade de São Paulo, São Paulo, 2022. Disponível em: https://www.teses.usp.br/teses/disponiveis/9/9132/tde-30112022-111709/. Acesso em: 27 dez. 2025. -
APA
Leão, M. de C. (2022). Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability (Tese (Doutorado). Universidade de São Paulo, São Paulo. Recuperado de https://www.teses.usp.br/teses/disponiveis/9/9132/tde-30112022-111709/ -
NLM
Leão M de C. Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability [Internet]. 2022 ;[citado 2025 dez. 27 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9132/tde-30112022-111709/ -
Vancouver
Leão M de C. Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability [Internet]. 2022 ;[citado 2025 dez. 27 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9132/tde-30112022-111709/ - Toxicity evaluation of docosahexaenoic acid nanoencapsulated with anti-PECAM-1
- Cytotoxicity and effectiveness in macrophage polarization of Annexin A1-surface-functionalized metal-complex multi-wall lipid core nanocapsule
- Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression
- Development of Annexin A1-surface-functionalized metal-complex multi-wall lipid core nanocapsules and effectiveness on experimental colitis
Informações sobre o DOI: 10.11606/T.9.2022.tde-30112022-111709 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
